Member of the GU Group
Dr Escudier is a MD, trained in Paris. He got his MD in 1981 as a cardiologist, and moved to Gustave Roussy Institute in 1983, initially in the Intensive Care Unit, and then took the lead of the Immunotherapy Unit, mainly in charge of developing programs in renal cell carcinoma and in melanoma. His largest fields of interest are renal cell carcinoma, immunotherapy (cytokines, vaccine), and development of new strategies (antiangiogenic drugs, gene therapy). He has been largely involved in the development of new targeted therapies for RCC, and has been the PI of many trials in the field of RCC, from phase I to phase III.
Dr Escudier is the head of the French Group of Immunotherapy since 1992, has been the chairman of the GU tumor board at Gustave Roussy Institute in Villejuif, France from 2010 to 2015.
He has been the chair of the GU Group of ESMO from 2008 to 2010, and is currently the ESMO faculty coordinator for the GU group. He has be leading the ESMO guidelines for kidney cancer in 2012, 2014 and 2016.
Dr Escudier is also part of the steering committee of KCA, and has been in the scientific committee of the European kidney cancer symposium from the first meeting 10 years ago until now. Dr Escudier is also president of ARTuR, the French association for research for renal tumors.
Dr Escudier is also leading the network CARARE, founded in 2013, devoted to rare kidney tumors in France.
He has published more than 370 papers in peer reviewed journals.